Pharmacy Times May 13, 2022
Aklilu Tedla, vice president of strategy and business development at Cardinal Health, discusses the cell and gene therapies in the pipeline for approval by the FDA.
Pharmacy Times interviewed Aklilu Tedla, vice president of strategy and business development at Cardinal Health, to discuss the future of pharmacies as more cell and gene therapy products become available to patients.
Question: What cell and gene therapies are in the pipeline that may be approved in the near future?
Aklilu Tedla: I think this is one of the periods where the FDA has a lot of cell and gene therapies on the docket for approval, and we expect that to accelerate over the coming years. Just to give 2 examples, there’s BioMarin’s hemophilia...
Today's Sponsors
Today's Sponsor